Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1006) 1006
Book Chapter (9) 9
Conference Proceeding (9) 9
Magazine Article (8) 8
Book Review (4) 4
Publication (3) 3
Book / eBook (2) 2
Patent (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (464) 464
life sciences & biomedicine (460) 460
humans (428) 428
hematology (354) 354
female (262) 262
male (252) 252
middle aged (244) 244
aged (226) 226
biological and medical sciences (191) 191
medical sciences (189) 189
adult (187) 187
oncology (184) 184
hematologic and hematopoietic diseases (149) 149
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (139) 139
aged, 80 and over (131) 131
myelodysplastic syndromes (121) 121
prognosis (116) 116
treatment outcome (114) 114
myelodysplastic syndromes - drug therapy (105) 105
abridged index medicus (97) 97
myelodysplastic syndromes - genetics (87) 87
risk factors (65) 65
adolescent (62) 62
life sciences (60) 60
myelodysplastic syndrome (59) 59
leukemia (57) 57
myelodysplastic syndromes - mortality (54) 54
chemotherapy (51) 51
myelodysplastic syndromes - pathology (51) 51
hematology, oncology and palliative medicine (49) 49
antineoplastic combined chemotherapy protocols - therapeutic use (48) 48
azacitidine - therapeutic use (48) 48
cancer (48) 48
myelodysplastic syndromes - therapy (48) 48
antimetabolites, antineoplastic - therapeutic use (47) 47
antineoplastic agents - therapeutic use (45) 45
mutation (45) 45
myelodysplastic syndromes - diagnosis (45) 45
follow-up studies (44) 44
antineoplastic agents (43) 43
leukemia, promyelocytic, acute - drug therapy (42) 42
remission induction (42) 42
survival analysis (42) 42
survival rate (41) 41
medicin och hälsovetenskap (40) 40
retrospective studies (39) 39
hemic and lymphatic diseases (38) 38
karyotyping (38) 38
pharmacology. drug treatments (38) 38
acute myeloid leukemia (37) 37
care and treatment (36) 36
recurrence (35) 35
azacitidine (33) 33
leukemia, myeloid, acute - genetics (33) 33
disease-free survival (32) 32
leukemia, myeloid, acute - drug therapy (32) 32
mds (30) 30
tumors (30) 30
disease progression (29) 29
leukemia, myeloid, acute - mortality (29) 29
time factors (29) 29
chromosome deletion (26) 26
cytogenetics (26) 26
myelodysplastic syndromes - complications (26) 26
research (26) 26
risk (26) 26
thalidomide - analogs & derivatives (26) 26
analysis (25) 25
thalidomide - therapeutic use (24) 24
tretinoin - therapeutic use (24) 24
young adult (24) 24
acute disease (23) 23
child (23) 23
immunology (23) 23
leukemia, myeloid - genetics (22) 22
bone marrow - pathology (21) 21
cohort studies (21) 21
patients (21) 21
animals (20) 20
lenalidomide (20) 20
survival (20) 20
translocation, genetic (20) 20
cell biology (19) 19
combined modality therapy (19) 19
cytarabine - administration & dosage (19) 19
france (19) 19
in situ hybridization, fluorescence (19) 19
leukemia, myeloid, acute - pathology (19) 19
apoptosis (18) 18
azacitidine - analogs & derivatives (18) 18
bone marrow (18) 18
clinical trials as topic (18) 18
drug administration schedule (18) 18
myelodysplastic syndromes - blood (18) 18
antineoplastic agents - adverse effects (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
chromosome aberrations (16) 16
genetic aspects (16) 16
hematopoietic stem cell transplantation (16) 16
myelodysplastic syndromes - etiology (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
by Thépot, Sylvain and Itzykson, Raphael and Seegers, Valerie and Recher, Christian and Raffoux, Emmanuel and Quesnel, Bruno and Delaunay, Jacques and Cluzeau, Thomas and Marfaing Koka, Anne and Stamatoullas, Aspasia and Chaury, Marie‐Pierre and Dartigeas, Caroline and Cheze, Stéphane and Banos, Anne and Morel, Pierre and Plantier, Isabelle and Taksin, Anne‐Laure and Marolleau, Jean Pierre and Pautas, Cecile and Thomas, Xavier and Isnard, Francoise and Beve, Blandine and Chait, Yasmine and Guerci, Agnes and Vey, Norbert and Dreyfus, Francois and Ades, Lionel and Ifrah, Norbert and Dombret, Herve and Fenaux, Pierre and Gardin, Claude and ALFA and GFM and GOELAMS and Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS)
American journal of hematology, ISSN 0361-8609, 04/2014, Volume 89, Issue 4, pp. 410 - 416
Life Sciences & Biomedicine | Hematology | Science & Technology | Azacitidine - adverse effects | Sepsis - etiology | Compassionate Use Trials | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Remission Induction | Antimetabolites, Antineoplastic - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Azacitidine - therapeutic use | Cohort Studies | Cytogenetics | Chemotherapy | Analysis | Cancer | Leukemia | Medical prognosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
by Castaigne, Sylvie, Prof and Pautas, Cécile, MD and Terré, Christine, MD and Raffoux, Emmanuel, MD and Bordessoule, Dominique, Prof and Bastie, Jean-Noel, Prof and Legrand, Ollivier, Prof and Thomas, Xavier, MD and Turlure, Pascal, MD and Reman, Oumedaly, MD and de Revel, Thierry, Prof and Gastaud, Lauris, MD and de Gunzburg, Noémie, MD and Contentin, Nathalie, MD and Henry, Estelle and Marolleau, Jean-Pierre, Prof and Aljijakli, Ahmad, MD and Rousselot, Philippe, Prof and Fenaux, Pierre, Prof and Preudhomme, Claude, Prof and Chevret, Sylvie, Prof and Dombret, Hervé, Prof and for the Acute Leukemia French Association and Acute Leukemia French Association
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9825, pp. 1508 - 1516
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Male | Survival Rate | Antineoplastic Agents - therapeutic use | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antineoplastic Agents - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Aminoglycosides - adverse effects | Aminoglycosides - therapeutic use | Bone marrow | Chemotherapy | Mutation | Transplants & implants | Toxicity | Drug dosages | Index Medicus | Abridged Index Medicus | Thrombocytopenia | Intravenous administration | Motivation | Antibodies | Clinical trials | Platelets | Gemtuzumab ozogamicin | Survival | Antineoplastic Agents | Aminoglycosides | Leukemia, Myeloid, Acute | Life Sciences | Antibodies, Monoclonal, Humanized | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
by Cluzeau, Thomas and Furstoss, Nathan and Savy, Coline and El Manaa, Wejdane and Zerhouni, Marwa and Blot, Lauriane and Calleja, Anne and Dufies, Maeva and Dubois, Alix and Ginet, Clemence and Mounier, Nicolas and Garnier, Georges and Raynaud, Sophie and Rohrlich, Pierre Simon and Peterlin, Pierre and Stamatoullas, Aspasia and Chermat, Fatiha and Fenaux, Pierre and Jacquel, Arnaud and Robert, Guillaume and Auberger, Patrick
International journal of molecular sciences, ISSN 1422-0067, 01/2020, Volume 21, Issue 1, p. 164
Biochemistry & Molecular Biology | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Recurrence | Ribonucleosides - therapeutic use | Apoptosis - drug effects | Leukemia, Myeloid, Acute - pathology | Aminoimidazole Carboxamide - therapeutic use | Humans | Middle Aged | Male | Clinical Trials as Topic | Aminoimidazole Carboxamide - pharmacology | Ribonucleosides - pharmacology | Aminoimidazole Carboxamide - analogs & derivatives | Treatment Failure | Cell Line, Tumor | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Cell Proliferation - drug effects | Myelodysplastic Syndromes - pathology | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | Drug Resistance, Neoplasm - drug effects | Index Medicus | aml | apoptosis | phase i/ii clinical trial | acadesine | mds | azacitidine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
by Gandhi Damaj and Alain Duhamel and Marie Robin and Yves Beguin and Mauricette Michallet and Mohamad Mohty and Stephane Vigouroux and Pierre Bories and Alice Garnier and Jean El Cheikh and Claude-Eric Bulabois and Anne Huynh and Jacques-Olivier Bay and Faeyzeh Legrand and Eric Deconinck and Nathalie Fegueux and Laurence Clement and Charles Dauriac and Natacha Maillard and Jérôme Cornillon and Lionel Ades and Gaelle Guillerm and Aline Schmidt-Tanguy and Zora Marjanovic and Sophie Park and Marie-Thérèse Rubio and Jean-Pierre Marolleau and Federico Garnier and ierre Fenaux and Ibrahim Yakoub-Agha
Journal of clinical oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4533 - 4540
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Azacitidine - adverse effects | Humans | Middle Aged | Induction Chemotherapy | Male | Treatment Outcome | Combined Modality Therapy | Myelodysplastic Syndromes - etiology | Antimetabolites, Antineoplastic - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Female | Retrospective Studies | Hematopoietic Stem Cell Transplantation - methods | Myelodysplastic Syndromes - surgery | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | Transplantation, Homologous - methods | Index Medicus | Myelodysplastic Syndromes | Hematopoietic Stem Cell Transplantation | Transplantation, Homologous | Life Sciences | Immunology | Azacitidine | Antimetabolites, Antineoplastic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Myelodysplastic syndromes
by Adès, Lionel, MD and Itzykson, Raphael, MD and Fenaux, Pierre, Prof
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 383, Issue 9936, pp. 2239 - 2252
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | T-Lymphocytes - physiology | Diagnosis, Differential | Prognosis | Humans | Treatment Outcome | Antineoplastic Agents - therapeutic use | Mutation - genetics | Myelodysplastic Syndromes - etiology | Myelodysplastic Syndromes - diagnosis | Myelodysplastic Syndromes - therapy | Stem Cell Transplantation - methods | Epigenesis, Genetic - genetics | Hematopoiesis - physiology | Cytogenetic Analysis | Myelodysplastic syndromes | Transplants & implants | Gene expression | Clinical outcomes | Genotype & phenotype | Chemotherapy | Older people | Medical prognosis | Bone marrow | Epigenetics | Cytogenetics | Mutation | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
by Kantarjian, Hagop and O'Brien, Susan and Ravandi, Farhad and Cortes, Jorge and Shan, Jianqin and Bennett, John M and List, Alan and Fenaux, Pierre and Sanz, Guillermo and Issa, Jean‐Pierre and Freireich, Emil J and Garcia‐Manero, Guillermo
Cancer, ISSN 0008-543X, 09/2008, Volume 113, Issue 6, pp. 1351 - 1361
prognosis in MDS | prognostic models | risk groups in MDS | chronic myelomonocytic leukemia | Prognosis in MDS | Prognostic models | Chronic myelomonocytic leukemia | Risk groups in MDS | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Models, Theoretical | Prognosis | Risk Assessment | Humans | Middle Aged | Myelodysplastic Syndromes - classification | Male | Survival Rate | Myelodysplastic Syndromes - diagnosis | Myelodysplastic Syndromes - therapy | Adolescent | Chromosome Aberrations | Aged, 80 and over | Adult | Female | Aged | Myelodysplastic Syndromes - genetics | Chromosomes, Human, Pair 7 - genetics | Blast Crisis | Models | Research | Health risk assessment | Myelodysplastic syndromes | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
by Guillermo Garcia-Manero and Pierre Fenaux
Journal of clinical oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 5, pp. 516 - 523
Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Erythropoietin - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Hematopoietic Stem Cell Transplantation | Azacitidine - analogs & derivatives | Recombinant Proteins | Transplantation, Homologous | Thalidomide - analogs & derivatives | Antimetabolites, Antineoplastic - therapeutic use | DNA Methylation | Myelodysplastic Syndromes - mortality | Epoetin Alfa | Thalidomide - therapeutic use | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | 5-aza-2'-deoxycytidine | Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?
by Robin, Marie and Fenaux, Pierre
Leukemia, ISSN 0887-6924, 10/2020, Volume 34, Issue 10, pp. 2552 - 2560
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Prognosis | Mortality | Stem cells | Cytogenetics | Development and progression | Transplantation | Hematopoietic stem cells | Myelodysplastic syndromes | Stem cell transplantation | Risk | Myelodysplastic syndrome | Hemopoiesis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights